Maseeh Uz Zaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maseeh Uz Zaman has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Nosheen Fatima
Section of PET/CT Imaging Services, Department of Radiology, Aga Khan University Hospital, Karachi, Pakistan
52 shared publicationsUnaiza Zaman
Department of Hem-Oncology, University of Oklahoma, OH, USA
23 shared publicationsAreeba Zaman
Department of Medicine, Sunny Downstate Medical Centre, NY, USA
22 shared publicationsRabia Tahseen
Department of Radiation Oncology, Aga Khan University Hospital, Karachi, Pakistan
15 shared publicationsSidra Zaman
Department of Internal Medicine, MedStar Health, Baltimore, Maryland, United States
12 shared publicationsZafar Sajjad
11 shared publications
Latest Publications
- Open Access
- 16 May 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (02) , 103-106
Cardiac Positron Emission Tomography Myocardial Perfusion Imaging: Seeing Beyond Perfusion
Positron emission tomography (PET) myocardial perfusion imaging (MPI) is a highly accurate noninvasive modality for evaluating coronary artery disease due to its excellent sensitivity and specificity, excellent image quality, efficient imaging protocol, and significantly lower radiation exposure. Its ability to absolutely quantify myocardial blood flow (MBF), MBF-R, and left ventricular ejection fraction-reserve also strengthens its diagnostic and prognostic properties and guides physicians about the justification for coronary revascularization. Presence of coronary artery calcification on the CT component indicates atherosclerosis, and its presence with normal PET MPI indicates subclinical nonobstructive coronaries and warrants risk factor medication to avoid future major adverse cardiac events. Metabolic imaging with FDG PET is considered the gold standard for diagnosing hibernating myocardium and helps in the management of sarcoidosis and infection of the cardiovascular system and implanted devices. However, the huge upfront and operational costs are the primary factors for the limited availability of PET MPI.
- 16 May 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (02) , 103-106
Open AccessCardiac Positron Emission Tomography Myocardial Perfusion Imaging: Seeing Beyond Perfusion
Positron emission tomography (PET) myocardial perfusion imaging (MPI) is a highly accurate noninvasive modality for evaluating coronary artery disease due to its excellent sensitivity and specificity, excellent image quality, efficient imaging protocol, and significantly lower radiation exposure. Its ability to absolutely quantify myocardial blood flow (MBF), MBF-R, and left ventricular ejection fraction-reserve also strengthens its diagnostic and prognostic properties and guides physicians about the justification for coronary revascularization. Presence of coronary artery calcification on the CT component indicates atherosclerosis, and its presence with normal PET MPI indicates subclinical nonobstructive coronaries and warrants risk factor medication to avoid future major adverse cardiac events. Metabolic imaging with FDG PET is considered the gold standard for diagnosing hibernating myocardium and helps in the management of sarcoidosis and infection of the cardiovascular system and implanted devices. However, the huge upfront and operational costs are the primary factors for the limited availability of PET MPI.
- Open Access
- 19 November 2024
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 24 (01) , 057-063
Role of 18FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study)
Background Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. Methods Patients with CUP referred for 18FDG PET/CT scan for detection of primary sites during the study period were recruited. 18FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). Results Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m2); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of 18FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative 18FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies (p > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of 18FDG PET/CT for detecting unknown primary (AUC 0.710; p ≤ 0.05; standard error = 0.0167; confidence interval: 0.647–0.768; vs. nonsignificant in parent study). Conclusion We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of 18FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of 18FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative 18FDG study could reduce FN results in patients with CUP. This study was approved by the ethical review committee of our JCI-accredited health care facility (ERC#: 2024-9755-28071). Article published online: 19 November 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 19 November 2024
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 24 (01) , 057-063
Open AccessRole of 18FDG PET/CT in Detecting Primary Tumors in Patients with Carcinoma of Unknown Primary: Single-Center Cross-Sectional Study from 2017 to 2023 (Extension Study)
Background Carcinoma of unknown primary (CUP) is a diverse group of cancers in which the primary tumor site remains occult despite detailed investigations. This is an extension of a published parent study with a smaller cohort, to further validate the published facts of detection efficiency of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT) in patients with CUP over a larger sample from 2017 to 2023. Methods Patients with CUP referred for 18FDG PET/CT scan for detection of primary sites during the study period were recruited. 18FDG PET/CT scan was acquired using a standardized protocol, and patients with suspected primary sites underwent biopsies. Scan findings and biopsy results were analyzed to find the detection rate, sensitivity, area under the curve (AUC), and positive predictive value (PPV). As no biopsy was performed in cases with negative scan, these cases were considered false negatives (FNs). Results Total 230 patients with CUP were included with similar demographic trend (mean age: 58 ± 14 years; 63% male and 37% female; mean body mass index: 26.82 ± 5.4 kg/m2); 138/230 (60 vs. 74% in parent study) patients were found to have a hypermetabolic focus suggestive of primary tumor sites and subjected to biopsy which turned out positive in 127/138 (true positive [TP]: 92 vs. 76% in parent study) and negative in 11/138 (true negative [TN]: 8 vs. 24% in parent study). Sensitivity and PPV of 18FDG PET/CT were 58 and 92%, respectively (68 and 76%, respectively, in parent study). The remaining 92/230 (40%) patients with negative 18FDG PET/CT for primary focus did not have biopsy. No significant demographic difference was seen in patients with TP and FN studies (p > 0.05). Receiver operating characteristics (ROC) curve revealed fair diagnostic strength of 18FDG PET/CT for detecting unknown primary (AUC 0.710; p ≤ 0.05; standard error = 0.0167; confidence interval: 0.647–0.768; vs. nonsignificant in parent study). Conclusion We conclude that this extension study with a larger cohort compared with the parent study has found a similar detection efficiency of 18FDG PET/CT for identifying primary tumor in patients with CUP (58 vs. 57%) but with better PPV and sensitivity. Upfront use of 18FDG PET/CT in CUP could preclude the use of many futile diagnostic procedures. Furthermore, the use of tumor-specific PET tracers, higher resolution scanners, and acquiring delayed images in patients with negative 18FDG study could reduce FN results in patients with CUP. This study was approved by the ethical review committee of our JCI-accredited health care facility (ERC#: 2024-9755-28071). Article published online: 19 November 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 1 November 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (11) , 3859-3864
Predictors for Disease-Free and Progression-Free Survivals in Metabolic Responders and Non-Responder on Follow-Up 18FDG PET/CT after Chemoradiation in Patients With Nasopharyngeal Cancer
Objective: To determine disease free survival (DFS) and progression free survival (PFS) and their predictors in patients with nasopharyngeal cancer (NPC) having achieved complete (CMR) and partial metabolic response (PMR) on post-chemoradiation (CRT) 18FDG PET/CT. Materials and Methods: Retro-prospective study conducted at PET/CT Section of JCIA accredited healthcare facility of Pakistan. Total 73 patients of NPC patients who had baseline and post-CRT 18FDG PET/CT were included and prospectively followed till predefined study end points of recurrence or disease progression or death from April-2016 till January 2024. Based on CMR on post-CRT 18FDG PET/CT, 45 patients labelled as responders while 28 with PMR as non-responders. Using logistic regression and ROC analysis, the predictors of recurrence and disease progression were analyzed in both groups. Kaplan Meier’s survival plots were analyzed to measure DFS in responders and PFS in non-responders respectively. Results: Body mass index (BMI), SUVmax and Stage-IV disease were found significantly higher in non-responder group. DFS in responders was significantly higher than PFS in non-responder (60.157 month ± 8.047 Vs 8.145 months ± 1.851). DFS was seen in 84% of responder group with 16% recurrence (7/45). Baseline SUVmax >14.2 and primary tumor size (PTS) > 41 mm were found significant predictors of recurrence in responder group. In the non-responder group, the PFS was found in 54% patients while 46% patients (n=13/28; 2 expired) had disease progression. No significant predictor was found for PFS in the non-responder group. In DFS the mean survival was significantly higher in patients with SUVmax ≤14.2 versus >14.2 (Mean Survival 67.390 vs. 38.283 months; Logrank 9.899; p=0.0017*). However, near significant difference was observed in non-responder group in their PFS at SUVmax ≤11.9 vs. >11.9 (Mean Survival 10.00 vs. 7.05 months; Logrank=3.096; p=0.0798). Conclusion: 18FDG PET/CT scan precisely stratifies the treated NPC patients into responders having longer DFS and non-responders having shorter PFS. Higher BMI, SUVmax of primary tumor and metastatic disease were found to have significant association in non-responders. In responders, PTS >41 mm and its SUVmax >14.2 were found significant predictors of recurrence. In non-responders, SUVmax >11.9 was found to have near significant association with disease progression.
- 1 November 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (11) , 3859-3864
Open AccessPredictors for Disease-Free and Progression-Free Survivals in Metabolic Responders and Non-Responder on Follow-Up 18FDG PET/CT after Chemoradiation in Patients With Nasopharyngeal Cancer
Objective: To determine disease free survival (DFS) and progression free survival (PFS) and their predictors in patients with nasopharyngeal cancer (NPC) having achieved complete (CMR) and partial metabolic response (PMR) on post-chemoradiation (CRT) 18FDG PET/CT. Materials and Methods: Retro-prospective study conducted at PET/CT Section of JCIA accredited healthcare facility of Pakistan. Total 73 patients of NPC patients who had baseline and post-CRT 18FDG PET/CT were included and prospectively followed till predefined study end points of recurrence or disease progression or death from April-2016 till January 2024. Based on CMR on post-CRT 18FDG PET/CT, 45 patients labelled as responders while 28 with PMR as non-responders. Using logistic regression and ROC analysis, the predictors of recurrence and disease progression were analyzed in both groups. Kaplan Meier’s survival plots were analyzed to measure DFS in responders and PFS in non-responders respectively. Results: Body mass index (BMI), SUVmax and Stage-IV disease were found significantly higher in non-responder group. DFS in responders was significantly higher than PFS in non-responder (60.157 month ± 8.047 Vs 8.145 months ± 1.851). DFS was seen in 84% of responder group with 16% recurrence (7/45). Baseline SUVmax >14.2 and primary tumor size (PTS) > 41 mm were found significant predictors of recurrence in responder group. In the non-responder group, the PFS was found in 54% patients while 46% patients (n=13/28; 2 expired) had disease progression. No significant predictor was found for PFS in the non-responder group. In DFS the mean survival was significantly higher in patients with SUVmax ≤14.2 versus >14.2 (Mean Survival 67.390 vs. 38.283 months; Logrank 9.899; p=0.0017*). However, near significant difference was observed in non-responder group in their PFS at SUVmax ≤11.9 vs. >11.9 (Mean Survival 10.00 vs. 7.05 months; Logrank=3.096; p=0.0798). Conclusion: 18FDG PET/CT scan precisely stratifies the treated NPC patients into responders having longer DFS and non-responders having shorter PFS. Higher BMI, SUVmax of primary tumor and metastatic disease were found to have significant association in non-responders. In responders, PTS >41 mm and its SUVmax >14.2 were found significant predictors of recurrence. In non-responders, SUVmax >11.9 was found to have near significant association with disease progression.
- Open Access
- 1 October 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (10) , 3577-3581
Impact of 18FDG PET/CT on Clinical Management, Cost Effectiveness, and Radiation Exposure in Newly Diagnosed Breast Cancer Patients
Background: For the initial staging of breast cancer (BC), 18FDG PET/CT is recommended by professional guidelines in stage III (except T3N1) and inflammatory BC (T4d) and optional when conventional imaging is equivocal or suspicious. However, growing evidence also supports its role in the staging of intermediate-risk groups (IIA, IIB, T3N1 of IA). This study aimed to compare the impact of 18FDG PET/CT with conventional imaging (CT-chest+abdomen+pelvis and bone scan; CT-CAP+BS) in staging, cost-effectiveness, and radiation exposure in the initial staging of BC. Material and Method: A retrospective study (April 2020 2024) included 115 biopsy-proven BC patients who had CT-CAP+BS and 18FDG PET/CT for initial staging. Data were analyzed to see the impact of 18FDG PET/CT on change in staging, cost-effectiveness, and radiation exposure compared to CA-CAP+BS. Results: Out of 115 patients (113 female and 02 male), 110 had unilateral and 5 had bilateral BC (Invasive Ductal Ca. 107; Non-IDC: 08) with non-significant laterality. The overall upstaging rate for regional nodal and/or distant metastases was 36% (24/66; excluded 49 with stage IV). The overall upstaging rate due to unsuspected higher nodal metastases was 20% (predominantly stage IIA, and IIB). Upstaging rate to stage IV was seen in 17% (11/66; predominantly in IIIA-C). The overall concordance (no change in staging) was seen in 64% (42/66) while no downstaging was found in any patient. In patients with stage-IV disease (n = 49), 18FDG PET/CT identified a higher number of hypermetabolic lesions in 18 (37%), lesser in 07 (14%), and similar in 24 (49%) cases. The estimated cost in Pak rupees for CT-CAP+BS and PET/CT was 139000 and 106000 respectively. The mean effective dose imparted by 18FDG PET/CT was 8.85 mSv compared to the reported 26.6 mSv by CT-CAP+BS. Conclusion: We conclude that in the initial staging of BC, 18FDG PET/CT compared with CT-CAP+BS has a significant impact on decision-making by upstaging the disease in stage II and III and detecting more metastatic lesions in stage-IV disease. Furthermore, 18FDG PET/CT is more cost-effective and imparts significantly lower radiation exposure as compared with CT+CAP+BS. These findings support the inclusion of 18FDG PET/CT in the initial staging of stage II-IV BC.
- 1 October 2024
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (10) , 3577-3581
Open AccessImpact of 18FDG PET/CT on Clinical Management, Cost Effectiveness, and Radiation Exposure in Newly Diagnosed Breast Cancer Patients
Background: For the initial staging of breast cancer (BC), 18FDG PET/CT is recommended by professional guidelines in stage III (except T3N1) and inflammatory BC (T4d) and optional when conventional imaging is equivocal or suspicious. However, growing evidence also supports its role in the staging of intermediate-risk groups (IIA, IIB, T3N1 of IA). This study aimed to compare the impact of 18FDG PET/CT with conventional imaging (CT-chest+abdomen+pelvis and bone scan; CT-CAP+BS) in staging, cost-effectiveness, and radiation exposure in the initial staging of BC. Material and Method: A retrospective study (April 2020 2024) included 115 biopsy-proven BC patients who had CT-CAP+BS and 18FDG PET/CT for initial staging. Data were analyzed to see the impact of 18FDG PET/CT on change in staging, cost-effectiveness, and radiation exposure compared to CA-CAP+BS. Results: Out of 115 patients (113 female and 02 male), 110 had unilateral and 5 had bilateral BC (Invasive Ductal Ca. 107; Non-IDC: 08) with non-significant laterality. The overall upstaging rate for regional nodal and/or distant metastases was 36% (24/66; excluded 49 with stage IV). The overall upstaging rate due to unsuspected higher nodal metastases was 20% (predominantly stage IIA, and IIB). Upstaging rate to stage IV was seen in 17% (11/66; predominantly in IIIA-C). The overall concordance (no change in staging) was seen in 64% (42/66) while no downstaging was found in any patient. In patients with stage-IV disease (n = 49), 18FDG PET/CT identified a higher number of hypermetabolic lesions in 18 (37%), lesser in 07 (14%), and similar in 24 (49%) cases. The estimated cost in Pak rupees for CT-CAP+BS and PET/CT was 139000 and 106000 respectively. The mean effective dose imparted by 18FDG PET/CT was 8.85 mSv compared to the reported 26.6 mSv by CT-CAP+BS. Conclusion: We conclude that in the initial staging of BC, 18FDG PET/CT compared with CT-CAP+BS has a significant impact on decision-making by upstaging the disease in stage II and III and detecting more metastatic lesions in stage-IV disease. Furthermore, 18FDG PET/CT is more cost-effective and imparts significantly lower radiation exposure as compared with CT+CAP+BS. These findings support the inclusion of 18FDG PET/CT in the initial staging of stage II-IV BC.
- 1 October 2024
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 34 (10) , 1145-1147
Detection of Hibernating Myocardium: A Gate Keeper in Decision Making in Patients with Left Ventricular Dysfunction
- 1 October 2024
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 34 (10) , 1145-1147
Detection of Hibernating Myocardium: A Gate Keeper in Decision Making in Patients with Left Ventricular Dysfunction
- 1 June 2024
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 34 (06) , 633-635
Dual Energy X-ray Absorptiometry (DXA) in the Management of Osteoporosis
- 1 June 2024
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 34 (06) , 633-635
Dual Energy X-ray Absorptiometry (DXA) in the Management of Osteoporosis
- Open Access
- 1 March 2024
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 39 (2) , 77-82
Prognostic Strength of CA 19-9, Demographic Parameters, and Maximum Standardized Uptake Value of Baseline 18F-FDG PET/CT in Treatment-naïve Patients with Pancreatic Carcinoma
Aim and Background: The aim of this study was to evaluate the prognostic value of imaging-based variables and tumor marker in predicting the progression-free survival (PFS) in treatment-naïve pancreatic cancer (PC) using baseline 18-fluorodeoxyglucose ( 18 FDG) positron emission tomography/computed tomography (PET/CT). Materials and Methods: This retro-prospective study was conducted at PET/CT imaging facility of JCIA health-care facility of Pakistan. Total 68 patients with PCs were retrospectively included who had 18 FDG PET/CT for staging from March 2017 to December 2020. Thirty-two patients had unresectable Stage IV disease on baseline imaging while the remaining 36 underwent Whipple’s procedure and both categories were followed by chemotherapy with/without immunotherapy. These patients were followed for a median period of 18 months (1–62 months) for PFS. Logistic regression analysis and receiver operating characteristic (ROC) analysis were used for independent predictors of patients’ demographics, tumor characteristics, CA 19-9, and maximum standardized uptake value (SUVmax) in PFS. Kaplan–Meier’s survival curves were analyzed to measure PFS using ROC-derived significant cutoff values of CA 19-9 and SUVmax. Results: Median PFS was 18 months (11-45) with 60% (41/68) patients were either died or labelled having metabolic progressive disease (MPD. Using logistic regression analysis, significant correlations were found for Stage IV disease and pancreatic body/tail tumor with disease progression (odd ratio: 7.535 and 4.803, respectively; P < 0.05). Gender, obesity, histological tumor type, and 18 FDG-avid regional nodes did not show a significant impact on PFS. On ROC analysis, SUVmax >5.3 of primary tumor and baseline CA 19-9 >197 U/ml were found to have a significant negative correlation with PFS (area under the curve: 0.827 and 0.911, respectively; P < 0.0001) and no association of age and primary tumor size in PFS. Significantly, shorter PFS was found using ROC-derived cutoff values of SUVmax >5.3 versus ≤5.3 of primary tumor (mean and 95% confidence interval [CI]: 16.7 vs. 48.5 and 10–23 vs. 41–56; log-rank = 25.014; P < 0.0001) and baseline CA 19-9 >197 versus ≤197 U/ml (mean and 95% CI: 11.8 vs. 46.9 and 7–16 vs. 39–55; log-rank = 38.217; P < 0.0001). Conclusion: SUVmax >5.3 of primary tumor and baseline CA 19-9 >197 U/ml were found to have a significant negative correlation with PFS in treatment-naïve PC patients. Among demographics, only Stage IV disease and pancreatic tail and body tumors were found to have a negative association with disease progression.
- 1 March 2024
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 39 (2) , 77-82
Open AccessPrognostic Strength of CA 19-9, Demographic Parameters, and Maximum Standardized Uptake Value of Baseline 18F-FDG PET/CT in Treatment-naïve Patients with Pancreatic Carcinoma
Aim and Background: The aim of this study was to evaluate the prognostic value of imaging-based variables and tumor marker in predicting the progression-free survival (PFS) in treatment-naïve pancreatic cancer (PC) using baseline 18-fluorodeoxyglucose ( 18 FDG) positron emission tomography/computed tomography (PET/CT). Materials and Methods: This retro-prospective study was conducted at PET/CT imaging facility of JCIA health-care facility of Pakistan. Total 68 patients with PCs were retrospectively included who had 18 FDG PET/CT for staging from March 2017 to December 2020. Thirty-two patients had unresectable Stage IV disease on baseline imaging while the remaining 36 underwent Whipple’s procedure and both categories were followed by chemotherapy with/without immunotherapy. These patients were followed for a median period of 18 months (1–62 months) for PFS. Logistic regression analysis and receiver operating characteristic (ROC) analysis were used for independent predictors of patients’ demographics, tumor characteristics, CA 19-9, and maximum standardized uptake value (SUVmax) in PFS. Kaplan–Meier’s survival curves were analyzed to measure PFS using ROC-derived significant cutoff values of CA 19-9 and SUVmax. Results: Median PFS was 18 months (11-45) with 60% (41/68) patients were either died or labelled having metabolic progressive disease (MPD. Using logistic regression analysis, significant correlations were found for Stage IV disease and pancreatic body/tail tumor with disease progression (odd ratio: 7.535 and 4.803, respectively; P < 0.05). Gender, obesity, histological tumor type, and 18 FDG-avid regional nodes did not show a significant impact on PFS. On ROC analysis, SUVmax >5.3 of primary tumor and baseline CA 19-9 >197 U/ml were found to have a significant negative correlation with PFS (area under the curve: 0.827 and 0.911, respectively; P < 0.0001) and no association of age and primary tumor size in PFS. Significantly, shorter PFS was found using ROC-derived cutoff values of SUVmax >5.3 versus ≤5.3 of primary tumor (mean and 95% confidence interval [CI]: 16.7 vs. 48.5 and 10–23 vs. 41–56; log-rank = 25.014; P < 0.0001) and baseline CA 19-9 >197 versus ≤197 U/ml (mean and 95% CI: 11.8 vs. 46.9 and 7–16 vs. 39–55; log-rank = 38.217; P < 0.0001). Conclusion: SUVmax >5.3 of primary tumor and baseline CA 19-9 >197 U/ml were found to have a significant negative correlation with PFS in treatment-naïve PC patients. Among demographics, only Stage IV disease and pancreatic tail and body tumors were found to have a negative association with disease progression.
- Open Access
- 22 January 2024
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 23 (01) , 001-002
Artificial Intelligence (AI) in Nuclear Medicine: Is a Friend Not Foe
Artificial intelligence (AI) is the most robust and fast-growing entity in current era that will revolutionize almost every corner of human lives. The term AI was first coined during a summer workshop at Dartmouth College, United States in 1956.[1] But, AI in current days has captured a front seat thanks to immense development in computing power, storage, advanced algorithm, and huge database. AI refers to an arena of computer science focused at replicating the performance of tasks typically requiring human intelligence.[2] Briefly humongous AI progress has been in the order of machine learning (ML), deep learning (DL), artificial neural networks (ANNs), convolutional neural networks (CNNs), and generative adversarial networks (GANs).[3] Discussing these entities is beyond the scope of this editorial. Precision medicine is aimed to develop tailor-made diagnostic and therapeutic approaches for individual patients. Integration of AI plays a significant role in achieving precision medicine in nuclear medicine (NM) and molecular imaging. AI has multifaceted applications in NM and molecular imaging including image planning, acquisition, processing, interpretation, diagnosis, prognosis, and prediction of response to therapy. On administrative side, it can also be used for patient admission and payments.[4] AI assimilated into patients' appointment and triage algorithms can significantly rationalize appointments, self/rescheduling and also prioritizing some visits.[5] For outpatients, AI has the potential to enable patients to determine a location and time that work best for them. Similarly, in admitted patient setting, AI algorithm can automatically prioritize certain NM examinations with the goal of optimizing patient care.[6] AI can also assess justification for requested procedure, contraindications based on history of allergies, and drug interference and also avoiding an unjustified repetition by evaluating prior studies conducted on same patient.[7] Daily quality control (QC) of NM scanners is important to ensure a scanner is properly functioning and in case of error it permits timely service calls to be placed, ensuring operational integrity and quality imaging. QC of NM/PET (positron emission tomography) scanners can take as little as 30 minutes or as long as 3 to 4 hours and nonavailability of imaging services. AI-based scanner acquires the QC data during off-hours and stores the information in the acquisition terminal for review and acceptance by the technologist that save precious time. So, AI-based QC systems can significantly improve the efficiency of NM technologists and departments throughput.[8] In future, AI would be integrated into patient verification algorithm at each step and smart syringe would allow automatic selection of radiopharmaceutical and radiopharmaceutical dose to be administered that can significantly reduce the chances of human errors.[9] After administration of radiopharmaceutical, many PET and NM studies require patients to wait in a secluded waiting environment for a certain period that is definitely a source of anxiety in some vulnerable patients. To mitigate patients' anxiety, emotionally intelligent AI-based devices like Smart Chatbots having a kind and loving temper to mimic the best of human empathy may be deployed.[10] One of important responsibilities of NM technologists is to select the correct scanning protocol depending on the prescribed NM test by the nuclear physician. Most of picture archiving and communication systems have integrated AI into protocol selection that can improve workflow efficiency by using available pertinent clinical information in the electronic health record.[11] AI can also be used to optimize contrast volume, injection rates based on patient characteristics, and selection of current field-of-view (FOV) based on information about location of lesion in previous study. So, AI can alert the NM technologist to ensure whether a particular area is included in current FOV or excluded by an educated decision making. During acquisition of NM and PET imaging, accelerating scanning time and reducing radiation dosage are promising aspects. In future, AI-based real-time image quality assessment evaluation may become a critical component of patient quality and safety data.[7] So, by adopting this methodology, technologists would be notified of image quality issues that would be corrected either by reacquisition or postacquisition data error correction. Certainly, this approach will decrease the need for patient recall that in NM has significant financial cost and unjustified radiation exposure.[7] AI can play an important role in processing of reconstructed NM and PET image for reducing noise, improving spatial resolution and extraction of image biomarkers for response evaluation in serial imaging. Various researchers have used large pixelated crystal with CNN to reduce noise and improve image resolution.[12] Another group has shown that use of denoising CNN in iterative PET reconstruction with local linear fitting has significantly reduced noise and improved image quality.[13] In NM and PET image processing, attenuation maps and scatter correction are one of topics for research. Hwang et al generated attenuation maps for whole-body positron emission tomography/magnetic resonance imaging (PET/MRI) using a specialized convolutional network architecture for image segmentation.[6] They have compared the CT-derived attenuation map to the Dixon-based 4-segment technique.[6] Prima facie, AI seems a threat to the role of the NM technologist; however, by automating mundane chore using AI, they can revisit their role as supervisor, overseeing AI-based QC and ensuring effective communication with patients. It is important that medical imaging professional societies and colleges should constitute task force to formulate and implement pertinent frameworks and guidelines. These guidelines must include basic standards for use and validation of...
- 22 January 2024
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 23 (01) , 001-002
Open AccessArtificial Intelligence (AI) in Nuclear Medicine: Is a Friend Not Foe
Artificial intelligence (AI) is the most robust and fast-growing entity in current era that will revolutionize almost every corner of human lives. The term AI was first coined during a summer workshop at Dartmouth College, United States in 1956.[1] But, AI in current days has captured a front seat thanks to immense development in computing power, storage, advanced algorithm, and huge database. AI refers to an arena of computer science focused at replicating the performance of tasks typically requiring human intelligence.[2] Briefly humongous AI progress has been in the order of machine learning (ML), deep learning (DL), artificial neural networks (ANNs), convolutional neural networks (CNNs), and generative adversarial networks (GANs).[3] Discussing these entities is beyond the scope of this editorial. Precision medicine is aimed to develop tailor-made diagnostic and therapeutic approaches for individual patients. Integration of AI plays a significant role in achieving precision medicine in nuclear medicine (NM) and molecular imaging. AI has multifaceted applications in NM and molecular imaging including image planning, acquisition, processing, interpretation, diagnosis, prognosis, and prediction of response to therapy. On administrative side, it can also be used for patient admission and payments.[4] AI assimilated into patients' appointment and triage algorithms can significantly rationalize appointments, self/rescheduling and also prioritizing some visits.[5] For outpatients, AI has the potential to enable patients to determine a location and time that work best for them. Similarly, in admitted patient setting, AI algorithm can automatically prioritize certain NM examinations with the goal of optimizing patient care.[6] AI can also assess justification for requested procedure, contraindications based on history of allergies, and drug interference and also avoiding an unjustified repetition by evaluating prior studies conducted on same patient.[7] Daily quality control (QC) of NM scanners is important to ensure a scanner is properly functioning and in case of error it permits timely service calls to be placed, ensuring operational integrity and quality imaging. QC of NM/PET (positron emission tomography) scanners can take as little as 30 minutes or as long as 3 to 4 hours and nonavailability of imaging services. AI-based scanner acquires the QC data during off-hours and stores the information in the acquisition terminal for review and acceptance by the technologist that save precious time. So, AI-based QC systems can significantly improve the efficiency of NM technologists and departments throughput.[8] In future, AI would be integrated into patient verification algorithm at each step and smart syringe would allow automatic selection of radiopharmaceutical and radiopharmaceutical dose to be administered that can significantly reduce the chances of human errors.[9] After administration of radiopharmaceutical, many PET and NM studies require patients to wait in a secluded waiting environment for a certain period that is definitely a source of anxiety in some vulnerable patients. To mitigate patients' anxiety, emotionally intelligent AI-based devices like Smart Chatbots having a kind and loving temper to mimic the best of human empathy may be deployed.[10] One of important responsibilities of NM technologists is to select the correct scanning protocol depending on the prescribed NM test by the nuclear physician. Most of picture archiving and communication systems have integrated AI into protocol selection that can improve workflow efficiency by using available pertinent clinical information in the electronic health record.[11] AI can also be used to optimize contrast volume, injection rates based on patient characteristics, and selection of current field-of-view (FOV) based on information about location of lesion in previous study. So, AI can alert the NM technologist to ensure whether a particular area is included in current FOV or excluded by an educated decision making. During acquisition of NM and PET imaging, accelerating scanning time and reducing radiation dosage are promising aspects. In future, AI-based real-time image quality assessment evaluation may become a critical component of patient quality and safety data.[7] So, by adopting this methodology, technologists would be notified of image quality issues that would be corrected either by reacquisition or postacquisition data error correction. Certainly, this approach will decrease the need for patient recall that in NM has significant financial cost and unjustified radiation exposure.[7] AI can play an important role in processing of reconstructed NM and PET image for reducing noise, improving spatial resolution and extraction of image biomarkers for response evaluation in serial imaging. Various researchers have used large pixelated crystal with CNN to reduce noise and improve image resolution.[12] Another group has shown that use of denoising CNN in iterative PET reconstruction with local linear fitting has significantly reduced noise and improved image quality.[13] In NM and PET image processing, attenuation maps and scatter correction are one of topics for research. Hwang et al generated attenuation maps for whole-body positron emission tomography/magnetic resonance imaging (PET/MRI) using a specialized convolutional network architecture for image segmentation.[6] They have compared the CT-derived attenuation map to the Dixon-based 4-segment technique.[6] Prima facie, AI seems a threat to the role of the NM technologist; however, by automating mundane chore using AI, they can revisit their role as supervisor, overseeing AI-based QC and ensuring effective communication with patients. It is important that medical imaging professional societies and colleges should constitute task force to formulate and implement pertinent frameworks and guidelines. These guidelines must include basic standards for use and validation of...
- Open Access
- 1 December 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (12) , 4053-4057
Morphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients
Background: In the current era vaccine-associated lymphadenopathy (VAL) is not an uncommon presentation on 18F-FDG PET/CT examinations in patients inoculated with Coronavirus disease 2019 (COVID-19) vaccination. In this study, we are presenting data of VAL on 18F-FDG PET/CT regarding its prevalence, temporal response to vaccination and imaging characteristics of VAL. Methods: Seventy-eight (78) consecutive vaccinated breast cancer (BC) patients who had 18FDG PET/CT were retrospectively analyzed. All patients had COVID-19 vaccine shots in contralateral arms and none in breast cancer site axilla (BSA). In 35 patients 18FDG avid nodes were found in vaccine site axilla (VSA). In 25 patients 18FDG avid nodes were found in BSA. Morphological criteria on CT images like size, presence of fatty hila and fat stranding of axillary nodes were analyzed. Metabolic criteria on PET images like SUVmax of nodes and liver as reference were also measured. Results: Out of 78 patients, 35 had positive nodes in VSA (45% prevalence) and 25/78 had BSA (33% prevalence). Mean duration of COVID-19 vaccination in each group was 8 ±04 week (non-significant p-value). On CT images, 18FDG avid nodes in VSA were significantly smaller (10 ± 03 mm) and with intact fatty hila without fat stranding than nodes in BSA with loss of fatty hila (25 ±10 mm; p <0.0001). Mean SUVmax of nodes in VSA was significantly lower (2.4 ±1.1) than nodes in BSA (10.2 ±5.5 – p-value 2 SD of Hepatic SUVmax were subjected to ultrasound guided fine needle aspiration (FNA) and turned out to be metastatic in nature. Conclusion: In COVID-19 vaccinated patients with BC, 18FDG avid nodes in VSA may pose diagnostic challenge. However, morphological (size < 10 mm short axis, intact fatty hila without fat stranding) and metabolic criteria (SUVmax 2 SD of hepatic SUVmax should be considered for FNA to rule out possible metastasis.
- 1 December 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (12) , 4053-4057
Open AccessMorphological and Metabolic Criteria of COVID-19 Vaccine Associated Axillary Nodes on 18-Fluorodeouxyglucose PET/CT Imaging in Breast Cancer Patients
Background: In the current era vaccine-associated lymphadenopathy (VAL) is not an uncommon presentation on 18F-FDG PET/CT examinations in patients inoculated with Coronavirus disease 2019 (COVID-19) vaccination. In this study, we are presenting data of VAL on 18F-FDG PET/CT regarding its prevalence, temporal response to vaccination and imaging characteristics of VAL. Methods: Seventy-eight (78) consecutive vaccinated breast cancer (BC) patients who had 18FDG PET/CT were retrospectively analyzed. All patients had COVID-19 vaccine shots in contralateral arms and none in breast cancer site axilla (BSA). In 35 patients 18FDG avid nodes were found in vaccine site axilla (VSA). In 25 patients 18FDG avid nodes were found in BSA. Morphological criteria on CT images like size, presence of fatty hila and fat stranding of axillary nodes were analyzed. Metabolic criteria on PET images like SUVmax of nodes and liver as reference were also measured. Results: Out of 78 patients, 35 had positive nodes in VSA (45% prevalence) and 25/78 had BSA (33% prevalence). Mean duration of COVID-19 vaccination in each group was 8 ±04 week (non-significant p-value). On CT images, 18FDG avid nodes in VSA were significantly smaller (10 ± 03 mm) and with intact fatty hila without fat stranding than nodes in BSA with loss of fatty hila (25 ±10 mm; p <0.0001). Mean SUVmax of nodes in VSA was significantly lower (2.4 ±1.1) than nodes in BSA (10.2 ±5.5 – p-value 2 SD of Hepatic SUVmax were subjected to ultrasound guided fine needle aspiration (FNA) and turned out to be metastatic in nature. Conclusion: In COVID-19 vaccinated patients with BC, 18FDG avid nodes in VSA may pose diagnostic challenge. However, morphological (size < 10 mm short axis, intact fatty hila without fat stranding) and metabolic criteria (SUVmax 2 SD of hepatic SUVmax should be considered for FNA to rule out possible metastasis.
- 1 December 2023
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 33 (12) , 1341-1343
18FDG PET/CT and Lung Cancer: Beaconhouse for Treating Oncologists
- 1 December 2023
- Published by College of Physicians and Surgeons Pakistan in Journal of the College of Physicians and Surgeons Pakistan
- Vol. 33 (12) , 1341-1343
18FDG PET/CT and Lung Cancer: Beaconhouse for Treating Oncologists